Ivabradine Sulfate

硫酸氢伊伐布雷定

Report date: 2026/02/07 20:00:33

Base Information

Drug NameIvabradine Sulfate
Drug Alias Name硫酸伊伐布雷定硫酸伊伐雷定
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHyperpolarization-activated cyclic nucleotide-gated channel blockers
TargetsHyperpolarization-activated cyclic nucleotide-gated channel
Therapy Area/IndicationsHealthy AgingMultiple Organ FailureVentricular Dysfunction, Left +[15] 
Global Approved IndicationsAngina, Stable
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2019/03/01
Country/TerritoryCanadaUnited StatesSweden +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarlos Iii Health InstituteJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Cairo UniversityMartin-Luther-Universitat Halle-Wittenberg +[7] 
Active IndicationsAngina, StableAtrial FibrillationHeart Diseases
Inactive IndicationsHealthy AgingMultiple Organ FailureVentricular Dysfunction, Left +[12] 

Other Information

ATC CodeC01EB17
Related LinksWikipediaDrugBank